NASDAQ:GDRX GoodRx (GDRX) Stock Forecast, Price & News $5.63 +0.10 (+1.81%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$5.52▼$5.6650-Day Range$5.40▼$9.2452-Week Range$3.82▼$9.37Volume855,088 shsAverage Volume884,650 shsMarket Capitalization$2.24 billionP/E Ratio187.73Dividend YieldN/APrice Target$8.44 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media GoodRx MarketRank™ ForecastAnalyst RatingHold2.36 Rating ScoreUpside/Downside49.9% Upside$8.44 Price TargetShort InterestBearish10.46% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.79Based on 5 Articles This WeekInsider TradingN/AProj. Earnings Growth25.00%From $0.08 to $0.10 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.39 out of 5 starsMedical Sector305th out of 971 stocksData Processing & Preparation Industry26th out of 58 stocks 4.2 Analyst's Opinion Consensus RatingGoodRx has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 5 buy ratings, 9 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.44, GoodRx has a forecasted upside of 49.9% from its current price of $5.63.Amount of Analyst CoverageGoodRx has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 2.0 Short Interest Percentage of Shares Shorted10.46% of the float of GoodRx has been sold short.Short Interest Ratio / Days to CoverGoodRx has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GoodRx has recently increased by 11.96%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldGoodRx does not currently pay a dividend.Dividend GrowthGoodRx does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GDRX. Previous Next 3.2 News and Social Media Coverage News SentimentGoodRx has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for GoodRx this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for GDRX on MarketBeat in the last 30 days. This is a decrease of -92% compared to the previous 30 days.MarketBeat Follows2 people have added GoodRx to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GoodRx insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.37% of the stock of GoodRx is held by insiders.Percentage Held by InstitutionsOnly 33.63% of the stock of GoodRx is held by institutions. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for GoodRx are expected to grow by 25.00% in the coming year, from $0.08 to $0.10 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GoodRx is 187.73, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 117.59.Price to Earnings Ratio vs. SectorThe P/E ratio of GoodRx is 187.73, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 122.72.Price to Book Value per Share RatioGoodRx has a P/B Ratio of 2.75. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About GoodRx (NASDAQ:GDRX) StockGoodRx Holdings, Inc., through its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices through GoodRx codes that are used to save money on prescriptions across the United States. It also offers other healthcare products and services, including subscriptions, pharma manufacturer solutions, and telehealth services. It serves pharmacy benefit managers that manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. GoodRx Holdings, Inc. was incorporated in 2015 and is headquartered in Santa Monica, California.Read More GDRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GDRX Stock News HeadlinesSeptember 29, 2023 | americanbankingnews.comGoodRx Holdings, Inc. (NASDAQ:GDRX) Given Consensus Recommendation of "Hold" by AnalystsSeptember 27, 2023 | seekingalpha.comGoodRx Faces Challenges In Subscription Plans, But Its Valuation Already Prices This InOctober 1, 2023 | Oxford Club (Ad)Better Than Oil StocksThe best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. September 26, 2023 | msn.comGoodRx Stock: Earnings Momentum Keeps It InterestingSeptember 21, 2023 | finance.yahoo.comICLR vs. GDRX: Which Stock Is the Better Value Option?September 21, 2023 | finance.yahoo.comGoodRx Announces Significant Savings on Antivirals, Medications and Vaccines for Cold & Flu SeasonSeptember 20, 2023 | msn.comDown -11.5% in 4 Weeks, Here's Why You Should You Buy the Dip in GoodRx Holdings, Inc. (GDRX)September 14, 2023 | markets.businessinsider.comWhat 15 Analyst Ratings Have To Say About GoodRx HoldingsOctober 1, 2023 | Legacy Research (Ad)Elon Did It Again: This Could be Bigger than TeslaLove him or hate him, it’s hard to deny Elon Musk is a genius. After revolutionizing online payment processing (PayPal), space exploration (SpaceX), and the auto industry (Tesla)... He’s getting ready to do it again with his new AI venture.September 13, 2023 | finance.yahoo.comGoodRx and MedImpact Announce Program to Ensure Seamless Access to Affordable PrescriptionsSeptember 11, 2023 | finance.yahoo.comGoodRx Now Offers 40% More Savings on Nearly 200 Medications at WalgreensSeptember 8, 2023 | barrons.comGoodRx Holdings Inc.September 6, 2023 | nasdaq.com3 Hot Stocks Under $10 for Your September WatchlistSeptember 1, 2023 | finance.yahoo.comAre GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Mixed Financials Driving The Negative Sentiment?August 30, 2023 | finance.yahoo.comGoodRx to Present at the Morgan Stanley Global Healthcare ConferenceAugust 30, 2023 | finance.yahoo.comGoodRx Launches Real-Time Benefit Check In Provider Mode To Offer Comprehensive Cost Information At The Point of PrescribingAugust 17, 2023 | msn.comGoodRx falls as CVS Caremark’s PBM contract loss weighsAugust 11, 2023 | msn.comDeutsche Bank Maintains GoodRx Holdings Inc - (GDRX) Hold RecommendationAugust 11, 2023 | msn.comJP Morgan Maintains GoodRx Holdings Inc - (GDRX) Neutral RecommendationAugust 11, 2023 | msn.comGuggenheim Maintains GoodRx Holdings Inc - (GDRX) Buy RecommendationAugust 11, 2023 | markets.businessinsider.comThese Analysts Boost Their Forecasts On GoodRx Holdings After Q2 ResultsAugust 11, 2023 | markets.businessinsider.com13 Analysts Have This to Say About GoodRx HoldingsAugust 10, 2023 | markets.businessinsider.comCredit Suisse Reaffirms Their Hold Rating on GoodRx Holdings (GDRX)August 10, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: TELA Bio (TELA), GoodRx Holdings (GDRX) and Mirati Therapeutics (MRTX)August 9, 2023 | finance.yahoo.comGoodRx (GDRX) Q2 2023 Earnings Call TranscriptAugust 9, 2023 | markets.businessinsider.comGoodRx Holdings Q2 Adj. Profit RisesAugust 9, 2023 | msn.comGoodRx Stock Tumbles After Q2 Report - Here's WhySee More Headlines Receive GDRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GoodRx and its competitors with MarketBeat's FREE daily newsletter. Email Address GDRX Company Calendar Last Earnings8/09/2023Today10/01/2023Next Earnings (Estimated)11/14/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Data processing & preparation Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:GDRX CUSIPN/A CIK1809519 Webwww.goodrx.com Phone855-268-2822FaxN/AEmployees952Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.44 High Stock Price Forecast$12.00 Low Stock Price Forecast$6.50 Forecasted Upside/Downside+49.9%Consensus RatingHold Rating Score (0-4)2.36 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)$0.03 Trailing P/E Ratio187.73 Forward P/E Ratio70.38 P/E GrowthN/ANet Income$-32,830,000.00 Net Margins1.58% Pretax Margin-1.52% Return on Equity2.44% Return on Assets1.26% Debt Debt-to-Equity Ratio0.73 Current Ratio11.14 Quick Ratio11.14 Sales & Book Value Annual Sales$745.09 million Price / Sales3.01 Cash Flow$0.23 per share Price / Cash Flow24.83 Book Value$2.05 per share Price / Book2.75Miscellaneous Outstanding Shares397,845,000Free Float392,395,000Market Cap$2.24 billion OptionableNot Optionable Beta1.13 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Trevor Bezdek (Age 45)Co-founder & Chairman Comp: $537kMr. Douglas Joseph Hirsch (Age 52)Co-founder, Chief Mission Officer & Director Comp: $507.29kMr. Karsten Ian Voermann (Age 53)CFO & Principal Financial Officer Comp: $693.69kMr. Raj Beri (Age 48)Chief Operating Officer Comp: $1.11MMr. Romin Nabiey (Age 36)Chief Accounting Officer & Principal Accounting Officer Comp: $516kMr. Scott W. Wagner (Age 52)Interim Chief Exec. Officer Ms. Whitney NotaroVP of Investor RelationsMr. Andrew Slutsky (Age 36)Chief Marketing Officer Ms. Vina M. Leite (Age 53)Chief People Officer Mr. Bansi Nagji (Age 58)Pres of Healthcare More ExecutivesKey CompetitorsAmphastar PharmaceuticalsNASDAQ:AMPHGemini TherapeuticsNASDAQ:GMTXNuVasiveNASDAQ:NUVACertaraNASDAQ:CERTPacific Biosciences of CaliforniaNASDAQ:PACBView All CompetitorsInstitutional OwnershipBarclays PLCBought 12,722 shares on 9/21/2023Ownership: 0.005%Wolverine Trading LLCBought 12,500 shares on 8/23/2023Ownership: 0.000%Virginia Retirement Systems ET ALBought 103,500 shares on 8/22/2023Ownership: 0.026%Osaic Holdings Inc.Sold 5,337 shares on 8/21/2023Ownership: 0.005%GTS Securities LLCBought 29,304 shares on 8/16/2023Ownership: 0.007%View All Institutional Transactions GDRX Stock - Frequently Asked Questions Should I buy or sell GoodRx stock right now? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GoodRx in the last year. There are currently 9 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" GDRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GDRX, but not buy additional shares or sell existing shares. View GDRX analyst ratings or view top-rated stocks. What is GoodRx's stock price forecast for 2023? 14 brokerages have issued 1 year price targets for GoodRx's shares. Their GDRX share price forecasts range from $6.50 to $12.00. On average, they anticipate the company's stock price to reach $8.44 in the next year. This suggests a possible upside of 49.9% from the stock's current price. View analysts price targets for GDRX or view top-rated stocks among Wall Street analysts. How have GDRX shares performed in 2023? GoodRx's stock was trading at $4.66 at the beginning of 2023. Since then, GDRX shares have increased by 20.8% and is now trading at $5.63. View the best growth stocks for 2023 here. When is GoodRx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023. View our GDRX earnings forecast. How were GoodRx's earnings last quarter? GoodRx Holdings, Inc. (NASDAQ:GDRX) issued its earnings results on Wednesday, August, 9th. The company reported $0.02 EPS for the quarter, beating analysts' consensus estimates of $0.01 by $0.01. The company earned $189.68 million during the quarter, compared to the consensus estimate of $186.90 million. GoodRx had a trailing twelve-month return on equity of 2.44% and a net margin of 1.58%. What ETFs hold GoodRx's stock? ETFs with the largest weight of GoodRx (NASDAQ:GDRX) stock in their portfolio include Invesco Next Gen Media and Gaming ETF (PBS), WisdomTree Growth Leaders Fund (PLAT) and Global X Telemedicine & Digital Health ETF (EDOC).IQ Chaikin U.S. Small Cap ETF (CSML). What guidance has GoodRx issued on next quarter's earnings? GoodRx updated its third quarter 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $186.00 million-$190.00 million, compared to the consensus revenue estimate of $192.58 million. What other stocks do shareholders of GoodRx own? Based on aggregate information from My MarketBeat watchlists, some companies that other GoodRx investors own include Gilead Sciences (GILD), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY), DraftKings (DKNG), GW Pharmaceuticals (GWPH), Rocket Companies (RKT), AT&T (T), Advanced Micro Devices (AMD) and Alteryx (AYX). When did GoodRx IPO? (GDRX) raised $900 million in an IPO on Wednesday, September 23rd 2020. The company issued 34,600,000 shares at a price of $24.00-$28.00 per share. Morgan Stanley, Goldman Sachs, J.P. Morgan and Barclays acted as the underwriters for the IPO and BofA Securities, Citigroup, Credit Suisse, RBC Capital Markets, UBS Investment Bank, Cowen, Deutsche Bank Securities, Evercore ISI, Citizens Capital Markets, KKR, LionTree, Raymond James, SVB Leerink, Academy Securities, Loop Capital Markets, R. Seelaus and Ramirez were co-managers. What is GoodRx's stock symbol? GoodRx trades on the NASDAQ under the ticker symbol "GDRX." How do I buy shares of GoodRx? Shares of GDRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is GoodRx's stock price today? One share of GDRX stock can currently be purchased for approximately $5.63. How much money does GoodRx make? GoodRx (NASDAQ:GDRX) has a market capitalization of $2.24 billion and generates $745.09 million in revenue each year. The company earns $-32,830,000.00 in net income (profit) each year or $0.03 on an earnings per share basis. How many employees does GoodRx have? The company employs 952 workers across the globe. How can I contact GoodRx? GoodRx's mailing address is 233 WILSHIRE BLVD. SUITE 990, SANTA MONICA CA, 90401. The official website for the company is www.goodrx.com. The company can be reached via phone at 855-268-2822 or via email at alex@blueshirtgroup.com. This page (NASDAQ:GDRX) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GoodRx Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.